Inpharma 1657 - 27 Sep 2008

■ Anticoagulant sales for STEMI (ST-elevationmyocardial infarction) are likely to double over thenext decade, according to a report by DecisionResources. Sales are predicted to increase from$US56.7 million in 2007 to over $US114 million by2017, largely due to the availability of neweranticoagulants with superior efficacy to unfractionatedheparin for STEMI treatment. Specifically, the patientshare of bivalirudin [Angiomax, Angiox] is expected togrow by about 16%, and fondaparinux sodium [Arixtra]by at least 9%, in France, Germany, Italy, Japan, Spain,the UK and the US.Decision Resources. Sales of Anticoagulants for the Treatment of St-ElevationMyocardial Infarction Will Double Over the Next 10 Years. Media Release :22 Sep 2008. Available from: URL: http://www.decisionresources.com 809093342

1

Inpharma 27 Sep 2008 No. 16571173-8324/10/1657-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved